Bank of America Issues Positive Forecast for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) had its price objective upped by Bank of America from $196.00 to $201.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the biotechnology company's stock.

ASND has been the subject of several other reports. Morgan Stanley upgraded Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $180.00 to $250.00 in a report on Monday, May 5th. Wedbush upped their price objective on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. The Goldman Sachs Group lifted their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Royal Bank of Canada increased their price target on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Finally, Evercore ISI lifted their price target on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $216.73.

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock traded down $0.71 during midday trading on Tuesday, reaching $173.69. The company had a trading volume of 537,095 shares, compared to its average volume of 490,350. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $183.00. The company has a market capitalization of $10.59 billion, a P/E ratio of -24.46 and a beta of 0.41. The firm's fifty day simple moving average is $157.71 and its 200-day simple moving average is $145.57.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The firm had revenue of $123.97 million for the quarter, compared to analysts' expectations of $98.56 million. On average, analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ASND. Point72 Asia Singapore Pte. Ltd. purchased a new position in Ascendis Pharma A/S in the 4th quarter valued at approximately $28,000. Jones Financial Companies Lllp grew its stake in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 197 shares in the last quarter. Brooklyn Investment Group increased its holdings in Ascendis Pharma A/S by 332.9% during the 1st quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 273 shares during the period. Blue Trust Inc. increased its holdings in Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 328 shares during the period. Finally, Quarry LP acquired a new stake in Ascendis Pharma A/S in the 4th quarter valued at about $96,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.